These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 7594705)
1. Phase I evaluation of zalcitabine administered to human immunodeficiency virus-infected children. Chadwick EG; Nazareno LA; Nieuwenhuis TJ; Massarella JW; de Dennis SR; Williams K; Yogev R J Infect Dis; 1995 Dec; 172(6):1475-9. PubMed ID: 7594705 [TBL] [Abstract][Full Text] [Related]
3. A pilot study of the bioavailability and pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS or AIDS-related complex. Gustavson LE; Fukuda EK; Rubio FA; Dunton AW J Acquir Immune Defic Syndr (1988); 1990; 3(1):28-31. PubMed ID: 2152803 [TBL] [Abstract][Full Text] [Related]
4. Effect of pregnancy, mode of administration and neonatal age on the pharmacokinetics of zalcitabine (2', 3'-dideoxycytidine) in the pigtailed macaque (Macaca nemestrina). Tuntland T; Nosbisch C; Unadkat JD J Antimicrob Chemother; 1997 Nov; 40(5):687-93. PubMed ID: 9421317 [TBL] [Abstract][Full Text] [Related]
6. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. Hughes W; McDowell JA; Shenep J; Flynn P; Kline MW; Yogev R; Symonds W; Lou Y; Hetherington S Antimicrob Agents Chemother; 1999 Mar; 43(3):609-15. PubMed ID: 10049275 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team. Bakshi SS; Britto P; Capparelli E; Mofenson L; Fowler MG; Rasheed S; Schoenfeld D; Zimmer B; Frank Y; Yogev R; Jimenez E; Salgo M; Boone G; Pahwa SG J Infect Dis; 1997 May; 175(5):1039-50. PubMed ID: 9129064 [TBL] [Abstract][Full Text] [Related]
8. The effects of renal impairment on the pharmacokinetics of zalcitabine. Bazunga M; Tran HT; Kertland H; Chow MS; Massarella J J Clin Pharmacol; 1998 Jan; 38(1):28-33. PubMed ID: 9597556 [TBL] [Abstract][Full Text] [Related]
9. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. Lewis LL; Venzon D; Church J; Farley M; Wheeler S; Keller A; Rubin M; Yuen G; Mueller B; Sloas M; Wood L; Balis F; Shearer GM; Brouwers P; Goldsmith J; Pizzo PA J Infect Dis; 1996 Jul; 174(1):16-25. PubMed ID: 8655986 [TBL] [Abstract][Full Text] [Related]
10. The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients. Nazareno LA; Holazo AA; Limjuco R; Passe S; Twardy SK; Min B; Massarella JW Pharm Res; 1995 Oct; 12(10):1462-5. PubMed ID: 8584481 [TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients. Jung D; AbdelHameed MH; Teitelbaum P; Dorr A; Griffy K J Clin Pharmacol; 1999 May; 39(5):505-12. PubMed ID: 10234599 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. van Leeuwen R; Katlama C; Kitchen V; Boucher CA; Tubiana R; McBride M; Ingrand D; Weber J; Hill A; McDade H J Infect Dis; 1995 May; 171(5):1166-71. PubMed ID: 7751691 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic evaluation of drug interactions with anti-human immunodeficiency virus drugs. V. Effect of soluble CD4 on 2',3'-dideoxycytidine kinetics in monkeys. Qian M; Swagler AR; Fong KL; Crysler CS; Mehta M; Gallo JM Drug Metab Dispos; 1992; 20(3):396-401. PubMed ID: 1355714 [TBL] [Abstract][Full Text] [Related]
14. Solid-phase extraction combined with radioimmunoassay for measurement of zalcitabine (2',3'-dideoxycytidine) in plasma and serum. Roberts WL; Buckley TJ; Rainey PM; Jatlow PI Clin Chem; 1994 Feb; 40(2):211-5. PubMed ID: 8313596 [TBL] [Abstract][Full Text] [Related]
15. The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients. Massarella JW; Nazareno LA; Passe S; Min B Pharm Res; 1996 Mar; 13(3):449-52. PubMed ID: 8692740 [TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of 2',3'-dideoxycytidine: an inhibitor of human immunodeficiency virus. Broder S Am J Med; 1990 May; 88(5B):2S-7S. PubMed ID: 1692446 [TBL] [Abstract][Full Text] [Related]
17. Studies of zidovudine in combination with didanosine and zalcitabine. Jablonowski H J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of 2',3'-dideoxycytidine in rats: application to interspecies scale-up. Ibrahim SS; Boudinot FD J Pharm Pharmacol; 1989 Dec; 41(12):829-34. PubMed ID: 2576444 [TBL] [Abstract][Full Text] [Related]
19. Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children. Yogev R; Kovacs A; Chadwick EG; Homans JD; Lou Y; Symonds WT Antimicrob Agents Chemother; 2005 Jan; 49(1):336-41. PubMed ID: 15616313 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of 2-fluorodideoxycytidine (2FddC) in patients infected with human immunodeficiency virus. Williams PE; Muirhead GJ; Sereni D; Rousseau FS; Edelman K; Hooker M Br J Clin Pharmacol; 1993 Mar; 35(3):255-60. PubMed ID: 8385974 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]